Get the Stockscreener App
15.04
1.25%
-0.19
Pre-market:
15.10
0.06
+0.40%
Schrodinger Inc stock is traded at $15.04, with a volume of 1.16M.
It is down -1.25% in the last 24 hours and up +13.08% over the past month.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
See More
Previous Close:
$15.23
Open:
$14.98
24h Volume:
1.16M
Relative Volume:
0.87
Market Cap:
$1.12B
Revenue:
$254.91M
Net Income/Loss:
$-103.48M
P/E Ratio:
-10.72
EPS:
-1.4036
Net Cash Flow:
$-148.35M
1W Performance:
+0.74%
1M Performance:
+13.08%
6M Performance:
-20.04%
1Y Performance:
-26.09%
1-Day Range:
$14.92
$15.71
1-Week Range:
$14.75
$16.30
52-Week Range:
$10.95
$23.75
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
15.04 | 1.12B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
159.71 | 25.94B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
66.84 | 13.12B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
48.61 | 8.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
84.92 | 7.10B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
70.38 | 5.45B | 646.34M | -512.40M | 202.76M | -6.6871 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Neutral |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrodinger (SDGR) director receives 8,141 RSUs and 13,313 stock options - Stock Titan
Form 4 Schrodinger Inc For: 23 June By Investing.com - Investing.com Canada
Director Jeffrey Chodakewitz receives RSUs and options at Schrodinger (SDGR) - Stock Titan
Schrodinger (NASDAQ: SDGR) director receives RSU and stock option grants - Stock Titan
Schrodinger (NASDAQ: SDGR) director receives RSUs and stock option grant - Stock Titan
Schrödinger (NASDAQ: SDGR) director receives new RSU and stock option awards - Stock Titan
Schrodinger (NASDAQ: SDGR) director granted RSUs and stock options in new Form 4 - Stock Titan
Schrodinger (SDGR) grants RSUs and stock options to director Nancy Thornberry - Stock Titan
Schrodinger, Inc. (SDGR) director granted RSUs and stock options - Stock Titan
Shareholders back Schrodinger (NASDAQ: SDGR) equity plan, director slate and KPMG - Stock Titan
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR) - Yahoo Finance
SDGR: All proposals passed and strategic focus remains on AI-driven molecular discovery innovation - TradingView
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On - Insider Monkey
What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal? - Insider Monkey
Schrodinger (SDGR) Issues Restricted Stock Units to New Employees - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Schrodinger Inc (SDGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
(SDGR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Schrodinger Inc (SDGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Schrodinger Inc (SDGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Schrodinger Inc (SDGR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Schrodinger Inc (SDGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Schrodinger Inc (SDGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Schrodinger Inc (SDGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It - Benzinga
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM) - The Globe and Mail
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating - Moomoo
SDGR Q1 2026 Earnings: EPS Misses Estimates as Company Focuses on Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
Schrödinger Finalizes Transition Terms for Former Commercial Chief - The Globe and Mail
Schrodinger finalizes separation agreement with former chief commercial officer - Investing.com
Schrodinger separation of Mannix Aklian as Chief Commercial Officer confirmed - TradingView
Severance package for ex-commercial chief at Schrödinger (NASDAQ: SDGR) - Stock Titan
(SDGR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Schrödinger’s Call Review: The Power of a Final Call - DualShockers
10 Top Tech Companies in Munich - Built In
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook? - simplywall.st
Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq - AD HOC NEWS
Schrödinger, Inc. Hits Day High with Strong 7.34% Intraday Surge - MarketsMojo
Schrödinger, Inc. Hits Day High with Strong Intraday Performance, Up 7.39% - Markets Mojo
Cheminformatics Market Size, Share | Growth Forecast [2034] - Fortune Business Insights
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth - Moomoo
Another Indie Matched Mina The Hollower's Review Scores This Week And No One Noticed - TheGamer
A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26 - GuruFocus
SDGR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Schrodinger Inc stock (US80655G1067): shares steady after May gains on Nasdaq - AD HOC NEWS
Schrödinger slides after early-stage trial data for cancer therapy - MSN
(SDGR) Risk Channels and Responsive Allocation - Stock Traders Daily
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets - Yahoo Finance
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):